...
首页> 外文期刊>Journal of the International Aids Society >The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD)
【24h】

The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD)

机译:亚洲常规临床环境中抗逆转录病毒替代治疗的结果;来自TREAT Asia HIV观察数据库(TAHOD)的数据

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretroviral regimen in virologically suppressed HIV‐infected patients in non‐clinical trial settings in Asian countries. Methods The study population consisted of HIV‐infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD). Individuals were included in this analysis if they started combination antiretroviral treatment (cART) after 2002, were being treated at a centre that documented a median rate of viral load monitoring ≥0.8?tests/patient/year among TAHOD enrolees, and experienced a minor or major treatment substitution while on virally suppressive cART. The primary endpoint to evaluate outcomes was clinical or virological failure (VF), followed by an ART class change. Clinical failure was defined as death or an AIDS diagnosis. VF was defined as confirmed viral load measurements ≥400?copies/mL followed by an ART class change within six months. Minor regimen substitutions were defined as within‐class changes and major regimen substitutions were defined as changes to a drug class. The patterns of substitutions and rate of clinical or VF after substitutions were analyzed. Results Of 3994 adults who started ART after 2002, 3119 (78.1%) had at least one period of virological suppression. Among these, 1170 (37.5%) underwent a minor regimen substitution, and 296 (9.5%) underwent a major regimen substitution during suppression. The rates of clinical or VF were 1.48/100?person years (95% CI 1.14 to 1.91) in the minor substitution group, 2.85/100?person years (95% CI 1.88 to 4.33) in the major substitution group and 2.53/100?person years (95% CI 2.20 to 2.92) among patients that did not undergo a treatment substitution. Conclusions The rate of clinical or VF was low in both major and minor substitution groups, showing that regimen substitution is generally effective in non‐clinical trial settings in Asian countries.
机译:引言尽管抗逆转录病毒疗法的替代通常是安全的,但大多数替代数据都是基于临床试验的结果。这项研究的目的是评估在亚洲国家的非临床试验环境中,用抗逆转录病毒疗法替代病毒抑制的HIV感染患者的治疗效果。方法研究人群包括参加TREAT Asia HIV观察数据库(TAHOD)的HIV感染患者。如果个人在2002年之后开始联合抗逆转录病毒治疗(cART),正在中心接受治疗,这些中心记录了TAHOD参加者中病毒载量监测的中位数比率≥0.8?测试/患者/年,并且经历过未成年人或在使用病毒抑制性cART时进行主要治疗替代。评估结果的主要终点是临床或病毒学衰竭(VF),然后是ART类别更改。临床失败被定义为死亡或艾滋病诊断。 VF定义为确认的病毒载量测量值≥400?拷贝/ mL,然后在六个月内进行ART类别更改。较小的方案替代定义为组内变更,主要方案的替代定义为药物类别的变更。分析了替代的模式和替代后的临床或VF率。结果2002年后开始接受抗病毒治疗的3994名成年人中,有3119名(78.1%)具有至少一个病毒学抑制期。其中,在抑制过程中,有1170个(37.5%)进行了次要的方案替代,而296个(9.5%)进行了次要的方案替代。次要替代组的临床或VF发生率为1.48 / 100?人年(95%CI 1.14至1.91),主要替代组为2.85 / 100?人年(95%CI 1.88至4.33)和2.53 / 100未接受治疗替代的患者中的患者每人年(95%CI 2.20至2.92)。结论在主要和次要替代组中,临床或VF发生率均较低,这表明在亚洲国家,方案替代在非临床试验中通常有效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号